These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 36282934)
1. Trends in endpoint use in pivotal trials and efficacy for US Food and Drug Administration-approved solid tumor therapies, 1995-2021. Alabaku O; Laffey TN; Suh K; Li M J Manag Care Spec Pharm; 2022 Nov; 28(11):1219-1223. PubMed ID: 36282934 [No Abstract] [Full Text] [Related]
2. Meaningful endpoints for therapies approved for hematologic malignancies. Smith BD; DeZern AE; Bastian AW; Durie BGM Cancer; 2017 May; 123(10):1689-1694. PubMed ID: 28222220 [TBL] [Abstract][Full Text] [Related]
3. A Survey of Survival Outcomes for Targeted Cancer Drugs Approved by the US Food and Drug Administration. He Q; Li Q; Lv F; Kaitin KI; Shao L Ther Innov Regul Sci; 2021 Jul; 55(4):676-684. PubMed ID: 33683659 [TBL] [Abstract][Full Text] [Related]
4. Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials. Chen EY; Joshi SK; Tran A; Prasad V JAMA Intern Med; 2019 May; 179(5):642-647. PubMed ID: 30933235 [TBL] [Abstract][Full Text] [Related]
5. Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price. Michaeli JC; Michaeli T; Trapani D; Albers S; Dannehl D; Würstlein R; Michaeli DT Breast Cancer; 2024 Nov; 31(6):1144-1155. PubMed ID: 39320645 [TBL] [Abstract][Full Text] [Related]
6. Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021. Michaeli DT; Michaeli T J Clin Oncol; 2022 Dec; 40(35):4095-4106. PubMed ID: 35921606 [TBL] [Abstract][Full Text] [Related]
7. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer. Ribeiro TB; Ribeiro A; Rodrigues LO; Harada G; Nobre MRC Int J Technol Assess Health Care; 2020; 36(1):20-28. PubMed ID: 31775939 [TBL] [Abstract][Full Text] [Related]
8. Feasibility of Randomized Controlled Trials for Cancer Drugs Approved by the Food and Drug Administration Based on Single-Arm Studies. Rittberg R; Czaykowski P; Niraula S JNCI Cancer Spectr; 2021 Aug; 5(4):. PubMed ID: 34409254 [TBL] [Abstract][Full Text] [Related]
9. The evidence base of US Food and Drug Administration approvals of novel cancer therapies from 2000 to 2020. Gloy V; Schmitt AM; Düblin P; Hirt J; Axfors C; Kuk H; Pereira TV; Locher C; Caquelin L; Walter-Claudi M; Lythgoe MP; Herbrand A; Kasenda B; Hemkens LG Int J Cancer; 2023 Jun; 152(12):2474-2484. PubMed ID: 36779785 [TBL] [Abstract][Full Text] [Related]
10. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016. Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262 [TBL] [Abstract][Full Text] [Related]
11. Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021. Benjamin DJ; Xu A; Lythgoe MP; Prasad V JAMA Netw Open; 2022 Mar; 5(3):e222265. PubMed ID: 35289858 [TBL] [Abstract][Full Text] [Related]
12. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101. Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ Oncologist; 2012; 17(1):13. PubMed ID: 22210086 [TBL] [Abstract][Full Text] [Related]
13. An empirical analysis of overall survival in drug approvals by the US FDA (2006-2023). Elbaz J; Haslam A; Prasad V Cancer Med; 2024 Apr; 13(8):e7190. PubMed ID: 38659418 [TBL] [Abstract][Full Text] [Related]
14. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials. Foster NR; Qi Y; Shi Q; Krook JE; Kugler JW; Jett JR; Molina JR; Schild SE; Adjei AA; Mandrekar SJ Cancer; 2011 Mar; 117(6):1262-71. PubMed ID: 20960500 [TBL] [Abstract][Full Text] [Related]
15. Clinical trial design and treatment effects: a meta-analysis of randomised controlled and single-arm trials supporting 437 FDA approvals of cancer drugs and indications. Michaeli DT; Michaeli T; Albers S; Michaeli JC BMJ Evid Based Med; 2024 Sep; 29(5):333-341. PubMed ID: 38760158 [TBL] [Abstract][Full Text] [Related]
16. Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019. Lythgoe MP; Desai A; Gyawali B; Savage P; Krell J; Warner JL; Khaki AR JAMA Netw Open; 2022 Jun; 5(6):e2216183. PubMed ID: 35687337 [TBL] [Abstract][Full Text] [Related]
17. An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate. Chen EY; Raghunathan V; Prasad V JAMA Intern Med; 2019 Jul; 179(7):915-921. PubMed ID: 31135822 [TBL] [Abstract][Full Text] [Related]
18. Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019. Dhodapkar M; Zhang AD; Puthumana J; Downing NS; Shah ND; Ross JS JAMA Netw Open; 2021 Jun; 4(6):e2113224. PubMed ID: 34110392 [TBL] [Abstract][Full Text] [Related]
19. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses. Blumenthal GM; Karuri SW; Zhang H; Zhang L; Khozin S; Kazandjian D; Tang S; Sridhara R; Keegan P; Pazdur R J Clin Oncol; 2015 Mar; 33(9):1008-14. PubMed ID: 25667291 [TBL] [Abstract][Full Text] [Related]
20. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review. Pease AM; Krumholz HM; Downing NS; Aminawung JA; Shah ND; Ross JS BMJ; 2017 May; 357():j1680. PubMed ID: 28468750 [No Abstract] [Full Text] [Related] [Next] [New Search]